ReviewPsoriasis (Auckland, N.Z.)2022
Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis.
Review in Psoriasis (Auckland, N.Z.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Prevalence of Psoriatic Arthritis in Patients with Moderate-to-Severe Psoriasis in the Era of Biologics and Small Molecule Therapies.Journal of clinical medicine · 2025Article
- Navigating the Journey in Psoriatic Arthritis: Matching the Right Patient, the Right Drug, and the Right Time.Journal of clinical medicine · 2025Article
- Molecular imaging of psoriatic arthritis.Current opinion in rheumatology · 2025Review
- Recent Advances in Gut Microbiota in Psoriatic Arthritis.Nutrients · 2025Review
- FGF7 as an essential mediator for the onset of ankylosing enthesitis related to psoriatic dermatitis.Life science alliance · 2025Article
- Patient Disease Characteristics and Treatment Patterns in Mild-Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study).Dermatology and therapy · 2025Article
- Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics.Archives of dermatological research · 2025Observational
- Are Systemic Drug Choices for Psoriasis by Dermatologists Compatible with Psoriatic Arthritis? Data from the German National Psoriasis Registry PsoBest.Psoriasis (Auckland, N.Z.) · 2025Article
- Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting.Advances in rheumatology (London, England) · 2024Article
- Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature.International journal of molecular sciences · 2024Review
- Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases.RMD open · 2024Article
- An Observational Study of 147 Psoriasis Patients: Overweightness and Obesity as a Significant Clinical Factors Correlated with Psoriasis.Medicina (Kaunas, Lithuania) · 2023Observational
- Disease modification in inflammatory skin disorders: opportunities and challenges.Nature reviews. Drug discovery · 2023Review
- Psoriatic Arthritis: Development, Detection and Prevention: A Scoping Review.Journal of clinical medicine · 2023Article
- Central Pain Sensitization in Patients with Chronic Plaque Psoriasis.Dermatology and therapy · 2023Article
- Advanced Glycation End Products and Psoriasis.Vaccines · 2023Review
- Could Targeted Pharmacotherapies Exert a "Disease Modification Effect" in Patients with Chronic Plaque Psoriasis?International journal of molecular sciences · 2022Review
- Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis.Biomedicines · 2022Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory arthritis associated with psoriasis, which may manifest with different domains such as dactylitis, enthesitis, synovitis and spondylitis. The estimated prevalence of PsA in patients with psoriasis ranges widely between 6% and 42%. In most cases, PsA is preceded by skin involvement by an average time of 7-8 years. In the complex patho-mechanisms involved in the transition from psoriasis to PsA, the gut and skin have been proposed as the sites of immune activation triggering or contributing to the development of PsA. In such a transition, a subclinical phase has been identified, characterized by enthesopathy where soluble biomarkers and imaging findings but no clinical symptoms are detectable. Recent studies have provided some evidence that timely treated psoriasis may reduce the risk of developing PsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.